We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 76

Competition Bureau sets out preliminary views on patent agreement settlement enforcement
  • Stikeman Elliott LLP
  • Canada
  • October 27 2014

On September 23, 2014, John Pecman, the Commissioner of Competition, delivered the keynote address at the George Mason University Pharma Conference


Health Canada releases guidance on “danger to human health or safety” posed by consumer products
  • Stikeman Elliott LLP
  • Canada
  • December 20 2013

Health Canada has released a guidance document on factors it will consider when determining whether a consumer product poses a "danger to human


Government seeks feedback on new drug safety initiatives
  • Stikeman Elliott LLP
  • Canada
  • May 6 2015

As previously reported, the Food and Drugs Act (the Act) has been substantively amended by Bill C-17, also known as Vanessa's Law; the Bill received


Bill C-17 (Vanessa’s Law) receives Royal Assent
  • Stikeman Elliott LLP
  • Canada
  • November 11 2014

Bill C-17, An Act to Amend the Foods and Drugs Act (Vanessa's Law) has received Royal Assent and will come into force on a date to be fixed by


Continuation of the "first to file" rule in Québec?
  • Stikeman Elliott LLP
  • Canada
  • September 14 2012

A recent decision from the Québec Superior Court has stated that the “first to file” rule continues to dictate the carriage of class actions within that province (except when it is obvious that the best interests of the putative class members are not the counsel’s priority), until such time as the Québec Court of Appeal changes the status quo


British Columbia Court of Appeal decertifies pharmaceutical class action
  • Stikeman Elliott LLP
  • Canada
  • March 13 2014

In Wakelam v. Wyeth Consumer Healthcare Wyeth Soins de Sante Inc., 2014 BCCA 36, the British Columbia Court of Appeal overruled a decision


Health and environmental claims an ongoing bureau focus
  • Stikeman Elliott LLP
  • Canada
  • December 18 2007

Investigations and enforcement actions over marketing and advertising claims related to health products and services have been a significant part of the Bureau's recent fair-business-practices work


Court of Appeal clarifies - for utility the promise of the patent must be "clear and unambiguous"
  • Stikeman Elliott LLP
  • Canada
  • August 21 2013

On July 24, 2013, the Federal Court of Appeal (FCA) issued its decision in Apotex Inc. v. Sanofi-Aventis, overturning a Federal Court decision


B.C. Court dismisses proposed class action against generic manufacturers of fentanyl patch
  • Stikeman Elliott LLP
  • Canada
  • July 8 2014

On June 20, 2014, Justice Bracken of the British Columbia Supreme Court dismissed a proposed class action against two generic manufacturers of


Employee dismissed for incomplete medical disclosure prior to hiring
  • Stikeman Elliott LLP
  • Canada
  • December 19 2011

Although the employee acted in good faith and did not voluntarily try to mislead her future employer by not revealing certain aspects of her medical history, the arbitrator in Association des policières et policiers provinciaux du Québec et Sûreté du Québec (K.T.) confirmed the employee’s dismissal on the grounds of vitiated of consent in the formation of the employment contract